David Hallal (L) and George Daley (Hallal photo: Bertrand Guay/AFP via Getty Images)

David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er de­tails

David Hal­lal’s El­e­vate­Bio is launch­ing a new com­pa­ny Thurs­day as it looks to con­tin­ue mak­ing its mark in the cell and gene ther­a­py spaces. But Hal­lal is al­so keep­ing his cards close to the vest, pre­fer­ring to toe the line be­tween bom­bast and mys­tique rather than go­ing all-in in one di­rec­tion.

The new com­pa­ny comes out of a part­ner­ship with Boston Chil­dren’s Hos­pi­tal and re­search from George Da­ley, the dean of Har­vard Med­ical School. The tri­umvi­rate claims to have found a way to de­sign bet­ter off-the-shelf cell ther­a­pies us­ing new meth­ods dis­cov­ered in Da­ley’s Boston Chil­dren’s Hos­pi­tal lab (Har­vard is not in­volved in the col­lab­o­ra­tion).

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters